Arbitel Plus 80 mg+12.5 mg Tablet (Telmisartan + HCT) – ACI Limited

1. About Arbitel Plus 80+12.5 mg (Telmisartan 80 mg + HCT)

Arbitel Plus 80+12.5 mg Tablet contains Telmisartan 80 mg (maximum-dose ARB) and Hydrochlorothiazide 12.5 mg (thiazide diuretic), manufactured by ACI Limited, Bangladesh. This is the target/maintenance formulation of the Arbitel Plus range — delivering the maximum telmisartan dose (80 mg, ONTARGET evidence) combined with low-dose HCT (12.5 mg) diuresis in a single once-daily tablet.

Arbitel Plus 80+12.5 mg is indicated for moderate-to-severe hypertension requiring dual ARB + diuretic therapy at maximal ARB dose, for patients not achieving blood pressure targets on Arbitel Plus 40+12.5 mg, or as a step-up from telmisartan 80 mg monotherapy when diuretic augmentation is needed. The ARB + thiazide combination amplifies antihypertensive efficacy through RAAS/volume dual blockade while telmisartan's aldosterone suppression partially protects against HCT-induced hypokalaemia.

2. Mechanism of Action

Telmisartan 80 mg (Maximum ARB Dose): Complete AT1 receptor blockade at maximum dose → full suppression of angiotensin II-mediated vasoconstriction, aldosterone secretion, and sympathetic activation. 24-hour RAAS suppression from once-daily dosing. PPAR-γ partial agonism at 80 mg contributes metabolic benefits (insulin sensitivity, lipid modulation). Biliary elimination — no renal dose adjustment needed.

Hydrochlorothiazide 12.5 mg: Na+/Cl− co-transporter inhibition in distal tubule → natriuresis and aquaresis → reduced blood volume → blood pressure reduction. Compensatory RAAS activation (renin/angiotensin II rise) is blocked by telmisartan, preventing diuretic resistance. Long-term peripheral vasodilation provides additional antihypertensive effect beyond volume reduction.

Combined advantage: HCT's volume depletion enhances telmisartan's ARB effect; telmisartan's RAAS blockade prevents HCT's compensatory RAAS escape and partially offsets HCT's hypokalaemia via aldosterone suppression. Net result: ~8–12 mmHg additional systolic BP reduction vs telmisartan 80 mg alone.

3. Indications

• Moderate-to-severe hypertension requiring maximum ARB + diuretic combination
• Step-up from Arbitel Plus 40+12.5 mg when BP remains above target
• Hypertension in patients on telmisartan 80 mg monotherapy who need additional diuretic effect
• Resistant hypertension as part of triple therapy (ARB + CCB + diuretic)
• FDC simplification for patients already on separate telmisartan 80 mg + HCT 12.5 mg tablets

4. Dosage and Administration

Standard: One tablet once daily, preferably morning. Provides telmisartan 80 mg + HCT 12.5 mg per day.

Maximum telmisartan dose: 80 mg/day. Maximum HCT antihypertensive dose 25 mg/day — Arbitel Plus 80+12.5 mg is at half the maximum HCT dose, providing efficacy with good tolerability.

Hepatic impairment: Telmisartan max 40 mg/day → use Arbitel Plus 40+12.5 mg instead. Arbitel Plus 80+12.5 mg contraindicated in moderate-severe hepatic impairment.

Take morning with or without food. Consistent daily timing.

5. Contraindications

• Hypersensitivity to telmisartan, HCT, or sulfonamides
• Pregnancy (all trimesters)
• Severe renal impairment (eGFR <30 ml/min)
• Severe hepatic impairment / biliary obstruction / cholestasis
• Anuria; refractory hypokalaemia, hyponatraemia, hypercalcaemia
• Aliskiren in diabetes or eGFR <60 ml/min

6. Warnings and Precautions

Pregnancy: Absolutely contraindicated. Both components teratogenic/fetotoxic.

Electrolytes: Monitor Na+, K+, Cl−. HCT hypokalaemia partially offset by telmisartan (aldosterone suppression), but monitor especially in CKD, elderly, concurrent corticosteroids. At 80 mg telmisartan, K+-sparing effect is maximal — hypokalaemia risk lower than with HCT alone.

Renal function: Monitor creatinine and eGFR. HCT ineffective below eGFR 30. Monitor for acute kidney injury (especially in bilateral RAS, dehydration, concomitant NSAIDs).

Hypotension: More pronounced than with either drug alone, especially in volume-depleted patients. At 80 mg telmisartan, higher BP-lowering effect — monitor first dose.

Glucose and uric acid: HCT at 12.5 mg has minimal metabolic effects but monitor in T2DM and gout-prone patients.

Hepatic impairment: Max telmisartan 40 mg in hepatic impairment. Use Arbitel Plus 40+12.5 mg instead.

7. Side Effects

Common: Dizziness (especially with 80 mg telmisartan), fatigue, headache, polyuria/nocturia (early treatment), back pain, URTI.

Uncommon: Hypokalaemia (attenuated vs HCT alone), hyponatraemia, elevated uric acid, impaired glucose tolerance, orthostatic hypotension.

Rare: Angioedema, photosensitivity (HCT), hepatic dysfunction, pancreatitis (HCT), thrombocytopenia.

No cough from telmisartan component — key advantage vs ACE-inhibitor combinations.

8. Drug Interactions

• NSAIDs: Reduce efficacy of both components; increase renal impairment risk — particularly important at 80 mg telmisartan
• Lithium: Both telmisartan and HCT raise lithium levels — close monitoring essential
• Digoxin: Telmisartan raises digoxin Cmax; HCT hypokalaemia potentiates digoxin toxicity — monitor levels
• Antidiabetics: HCT may reduce glycaemic control — adjust if needed
• Cholestyramine: Reduces HCT absorption — take Arbitel Plus 1h before or 4–6h after
• Dual RAAS (ACE inhibitor/aliskiren): Avoid in diabetic CKD

9. Telmisartan 80 mg + HCT 12.5 mg: Clinical Evidence

Multiple RCTs with the telmisartan 80 mg + HCT 12.5 mg combination demonstrate superior BP reduction vs either component alone: additional ~8–12 mmHg systolic over telmisartan 80 mg monotherapy, with 24-hour ABPM (ambulatory blood pressure monitoring) confirming maintained nocturnal and early morning coverage. Compared to HCT alone, the combination prevents compensatory RAAS activation that limits diuretic efficacy, protects against hypokalaemia, and adds PPAR-γ metabolic benefits. The ONTARGET-established cardiovascular protection of telmisartan 80 mg is preserved in the combination.

10. Triple Therapy: Arbitel Plus 80+12.5 mg + Amlodipine

For patients with resistant hypertension (BP above target on dual therapy), adding amlodipine to Arbitel Plus 80+12.5 mg creates a complete ARB + thiazide + CCB triple regimen — the evidence-based backbone for resistant hypertension. This combination targets three distinct mechanisms: RAAS blockade (telmisartan), volume depletion (HCT), and arteriolar vasodilation (amlodipine). PATHWAY-2 and ASCOT trial evidence supports the addition of amlodipine to existing ARB + diuretic for resistant hypertension.

11. Hypertension Stepping Strategy in Bangladesh

ACI Limited's Arbitel range provides a complete step-up treatment pathway: Arbitel 20/40/80 mg (monotherapy by dose) → Arbitel AM 5+40/5+80 mg (ARB + CCB) or Arbitel Plus 40+12.5/80+12.5 mg (ARB + diuretic) → Triple therapy (both combinations). Arbitel Plus 80+12.5 mg represents the maximum-dose ARB + diuretic dual therapy — typically step 3 in the treatment algorithm before triple therapy is considered.

12. Storage

• Below 30°C, cool, dry, protected from moisture and light
• Morning dosing recommended. Original blister. Keep from children.
• Do not use after expiry date.

Frequently Asked Questions (FAQ)

Q1: What is Arbitel Plus 80+12.5 mg used for?

Arbitel Plus 80+12.5 mg combines Telmisartan 80 mg (maximum ARB dose) and Hydrochlorothiazide 12.5 mg for moderate-to-severe hypertension requiring dual ARB + diuretic therapy. It is the target/maintenance dose of the Arbitel Plus range — used when Arbitel Plus 40+12.5 mg is insufficient for BP control, or when maximum telmisartan RAAS blockade (ONTARGET evidence for cardiovascular protection) is needed alongside diuresis. Provides ~8–12 mmHg additional systolic BP reduction vs telmisartan monotherapy through complementary mechanisms.

Q2: Is Arbitel Plus 80+12.5 mg safe for long-term use?

Yes — both telmisartan and HCT have established long-term safety profiles when properly monitored. Telmisartan is safe for indefinite use with annual monitoring of BP, renal function (creatinine/eGFR), and serum potassium. HCT at 12.5 mg has a good long-term safety record with minimal metabolic effects at this low dose — significantly better than the 25–50 mg doses historically associated with glucose, lipid, and electrolyte problems. Annual uric acid monitoring is prudent in patients with gout history. Vitamin B12 is not affected (unlike metformin).

Q3: How does Arbitel Plus 80+12.5 mg compare to Arbitel AM 5+80 mg?

Both contain telmisartan 80 mg but differ in the second component: Arbitel AM 5+80 mg pairs telmisartan with amlodipine (CCB), while Arbitel Plus 80+12.5 mg pairs it with HCT (diuretic). Clinical guidelines suggest ARB + CCB (Arbitel AM) is preferred for: T2DM patients with nephropathy, patients with angina, metabolically active patients (CCBs are lipid/glucose neutral). ARB + diuretic (Arbitel Plus) is preferred for: patients with fluid overload or oedema, those with isolated systolic hypertension, or as the second combination in a triple regimen. Both provide excellent BP control — the choice depends on individual patient characteristics.

Q4: Can Arbitel Plus 80+12.5 mg be used if I have both hypertension and diabetes?

Yes — with monitoring. Telmisartan 80 mg is among the preferred antihypertensives for T2DM given its renoprotection and PPAR-γ metabolic benefits. HCT 12.5 mg has minimal glucose-raising effect at this dose. However, monitor blood glucose when initiating Arbitel Plus in diabetic patients, and ensure your diabetologist is aware to adjust antidiabetic medications if needed. Do not use in diabetic patients with severe CKD (eGFR <30 ml/min) — HCT is ineffective and potentially harmful at this level. Use Arbitel 80 mg alone or Arbitel AM 5+80 mg instead.